Johnson & Johnson (NYSE:JNJ) ranks among the stocks to benefit from an onshoring boom. On July 23, Erste Group raised the ...

Johnson & Johnson N/A must pay more than US$42-million to a Massachusetts man who alleges that he developed mesothelioma, a ...

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it launched its VirtuGuide AI-powered, patient-matched Lapidus ...

Tuesday, July 29, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc.

Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New ...

Johnson & Johnson (NYSE: JNJ) and Verizon (NYSE: VZ) stand out among Dow stocks for their high dividend yields and ...

Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

With August tariff extensions looming, several major companies are now guiding for reduced tariff impacts, a shift that has ...

U.S. companies are removing their CEOs at the fastest clip in two decades, data shows, as increased scrutiny from ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Kenvue took action after three U.S. hedge funds -- Starboard Value, Tom’s Capital and Third Point – agitated for change at the company, and Starboard CEO Jeffrey Smith got a board seat in March to ...